Logo image of VRX

VALEANT PHARMACEUTICALS INTL I (VRX) Stock Price, Forecast & Analysis

USA - New York Stock Exchange - NYSE:VRX - CA91911K1021

23.4
-0.83 (-3.43%)
Last: 7/13/2018, 8:04:05 PM
23.36
-0.04 (-0.17%)
After Hours: 7/13/2018, 8:04:05 PM

VRX Key Statistics, Chart & Performance

Key Statistics
Market Cap8.16B
Revenue(TTM)8.61B
Net Income(TTM)-917.00M
Shares348.71M
Float331.27M
52 Week High27.79
52 Week Low10.94
Yearly Dividend0
Dividend Yield0%
EPS(TTM)3.96
PE5.91
Fwd PE6.74
Earnings (Next)N/A N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A


VRX short term performance overview.The bars show the price performance of VRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

VRX long term performance overview.The bars show the price performance of VRX in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30

The current stock price of VRX is 23.4 null. In the past month the price decreased by -12.69%. In the past year, price increased by 35.73%.

VALEANT PHARMACEUTICALS INTL I / VRX Daily stock chart

VRX Latest News, Press Relases and Analysis

About VRX

Company Profile

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.

Company Info

VALEANT PHARMACEUTICALS INTL I

2150 ST. ELZEAR BLVD. WEST

LAVAL A8 H7L 4A8

CEO: Joseph C. Papa

Phone: 514-744-6792

VALEANT PHARMACEUTICALS INTL I / VRX FAQ

What does VRX do?

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.


What is the current price of VRX stock?

The current stock price of VRX is 23.4 null. The price decreased by -3.43% in the last trading session.


Does VALEANT PHARMACEUTICALS INTL I pay dividends?

VRX does not pay a dividend.


What is the ChartMill rating of VALEANT PHARMACEUTICALS INTL I stock?

VRX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Who owns VALEANT PHARMACEUTICALS INTL I?

You can find the ownership structure of VALEANT PHARMACEUTICALS INTL I (VRX) on the Ownership tab.


VRX Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to VRX. When comparing the yearly performance of all stocks, VRX is one of the better performing stocks in the market, outperforming 90.59% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

VRX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to VRX. While VRX is still in line with the averages on profitability rating, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VRX Financial Highlights

Over the last trailing twelve months VRX reported a non-GAAP Earnings per Share(EPS) of 3.96. The EPS decreased by -29.98% compared to the year before.


Industry RankSector Rank
PM (TTM) -10.65%
ROA -2.56%
ROE -20.27%
Debt/Equity 5.59
Chartmill High Growth Momentum
EPS Q2Q%-68.21%
Sales Q2Q%-5.41%
EPS 1Y (TTM)-29.98%
Revenue 1Y (TTM)-8.51%

VRX Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next Y-12.27%
Revenue Next YearN/A

VRX Ownership

Ownership
Inst Owners0.13%
Ins Owners1.27%
Short Float %N/A
Short RatioN/A